TSC2 and neoplasm with perivascular epithelioid cell differentiation: Mutations in the TSC1/TSC2 genes lead to activation of the mammalian target of rapamycin (mTOR) signaling pathway, which is the molecular basis for the clinical application of mTOR pathway inhibitors for the treatment of PEComa.